State of M&A Data Rooms — Q2 2026 Read the report →
Peony LogoPeony

How to Sell a Beauty Brand (2026): Valuation, Buyers, Process

M&A advisory at Peony. Former investment banker at Moelis & Company, where I worked on cross-border M&A across healthcare, industrials, and consumer. I write about how deals actually get diligenced and closed.

Connect with me on LinkedIn! I want to help you :)
ConsumerBeautyM&ABrand SaleValuationCPG

Last updated: August 2026

I'm Chris Chen. Before joining Peony, I worked in M&A at Moelis & Company across cross-border, healthcare, industrials, and consumer transactions. Beauty was one of the busiest corners of that consumer coverage, and it is a category where the deal tape tells you more than any valuation textbook: the way e.l.f. structured its rhode purchase, the gap between a headline price and an all-in price on Touchland, whether L'Oréal's Medik8 deal actually closed — read the structures and you learn exactly what beauty acquirers are afraid of and what they will pay up for. This guide is the honest version: what your brand is worth in 2026, who buys, what they diligence, how the process runs, the structures you should expect, and — because it matters — when you should not sell at all.

Let me be clear up front about what this post is and is not. I run Peony, a data room company serving 6,800+ customers, so I see the confidential side of a lot of these processes. But the deal facts below come from public reporting on public deals — SEC filings, company press releases, and the beauty M&A reports the banks publish — not from anything I see inside a room. Where a number is a range or an estimate, I say so. Where a deal was announced but not confirmed closed, I say that too, because in beauty the difference between "agreed to acquire" and "acquired" is the whole story.

Quick answer. A beauty brand's value is driven by profitability and growth, not revenue alone: Capstone Partners pegs the sector at roughly 3.6x EV/revenue (Capstone Partners Beauty M&A Report, July 2025), and its later December 2025 update puts the beauty and personal care EV/EBITDA average at 14.9x (Capstone Partners Beauty M&A Update, December 2025) — versus roughly 1.9x revenue and 11.2x EBITDA for consumer overall. Three buyer classes compete: strategics (e.l.f., L'Oréal, Unilever, Church & Dwight), private equity (L Catterton, Bansk), and holding groups (THG). The 2025 tape sets the top end — e.l.f./rhode closed at ~$1B ($800M at close plus a $200M earnout), Church & Dwight/Touchland closed at a reported ~6.8x revenue — but the same diligence that justifies those prices (scan-data verification, retailer concentration, formula ownership, MoCRA compliance) is where a padded, influencer-built P&L gets repriced. Run a confidential process against several fitting buyers rather than reacting to one inbound. For the general exit decision, see our business exit planning guide; this post is beauty-specific.

This guide stays in its lane. It owns beauty valuation, the acquirer landscape, beauty value drivers, beauty diligence, and beauty deal structures. If you are raising money rather than selling, our consumer investors rundown covers the VC side, and our fundraising CPG data room guide covers the document mechanics of a raise. If you are the buyer building a platform, the roll-up data room guide covers the acquirer-side mechanics. This post is for the founder on the sell side.

What is a beauty brand actually worth in 2026?

A beauty brand's worth is set by its margin structure and growth rate first and its revenue line second — the multiple bands are wide, and where you land inside them is decided by whether you are profitable, growing, and clean on velocity and formula ownership. The category commands a premium to the rest of consumer, but that premium is earned by the specific attributes below, not handed to every brand with "beauty" in its description.

Start with the anchor numbers, attributed to their sources so you can check them. Capstone Partners' beauty coverage puts sector M&A at roughly 3.6x EV/revenue (Capstone Partners Beauty M&A Report, July 2025), and Capstone's more recent December 2025 update pegs the beauty and personal care EV/EBITDA average at 14.9x (Capstone Partners Beauty M&A Update, December 2025). Both sit well above the broader consumer industry, which Capstone puts at about 1.9x EV/revenue and 11.2x EV/EBITDA. On the public side, Capstone's beauty comp set trades around 2.0x EV/revenue and 13.0x EV/EBITDA at a roughly 19.9% median EBITDA margin — which tells you the public market pays for margin, and that the private premium sits on top of scarcity and growth.

Now the distribution around those averages, because it is enormous. Prestige and premium brands generally clear 3x to 5x revenue, and the scarce, breakout, celebrity-attached assets — the ones a strategic decides it must own — run 5x to 8x-plus revenue (Capstone Partners Beauty M&A Update). That top band is the tail, not the average; do not underwrite your own outcome to it unless you genuinely have a scarce, on-trend, fast-growing brand. And the floor is real too: an unprofitable DTC brand whose growth is bought with paid media at rising customer-acquisition cost often cannot get a strategic to engage, because the moment diligence normalizes that spend the profitability disappears. Profitable-and-growing clears the bar; cash-burning-and-hoping usually does not.

The reason to read the deal tape is that it disciplines those bands with actual prices. Here is the 2025-26 evidence, each deal stated exactly at its verified status — because in beauty, "announced" and "closed" are different facts:

  • e.l.f. Beauty / rhode — closed August 5, 2025. e.l.f. acquired Hailey Bieber's rhode for approximately $1 billion in total consideration: $800 million at closing ($600 million cash plus $200 million in stock), plus an earnout of up to $200 million over three years. rhode had roughly $212 million in net sales for the fiscal year ended March, an implied ~4.7x EV/revenue, and Bieber stayed on as chief creative officer (e.l.f. Beauty press release, May 28, 2025; e.l.f. Beauty SEC 8-K confirming the August 5 close).
  • Church & Dwight / Touchland — closed July 16, 2025. The headline was ~$700 million plus an earn-out; the all-in figure is ~$880 million per Latham & Watkins, which advised the deal — $700 million at closing in cash plus Church & Dwight restricted stock, and an earn-out of up to $180 million tied to Touchland's 2025 net sales. Touchland did roughly $130 million in net sales and ~$55 million of EBITDA on a trailing-twelve-month basis through March 2025, an implied ~6.8x EV/revenue and 16.0x EV/EBITDA per Capstone (Church & Dwight press release, May 12, 2025; Latham & Watkins deal note). State both numbers when you cite this one — the $700M headline and the ~$880M all-in are the same deal.
  • Unilever / Dr. Squatch — closed November 16, 2025. Unilever announced the deal on June 23, 2025 and closed it that November, buying the men's personal-care brand from Summit Partners at a reported ~$1.5 billion, a price reported by the Financial Times rather than confirmed in Unilever's own release (Unilever press release; FT-reported price via Investing.com). Treat the price as reported, not company-confirmed.
  • L'Oréal / Medik8 — announced June 9, 2025, not confirmed closed. L'Oréal agreed to acquire a majority stake in the British skincare brand (with Inflexion retaining a minority) at an enterprise value of roughly €1 billion / ~$1.1 billion, subject to regulatory approval (L'Oréal press release; Beauty Independent). As of this writing it is signed and pending — "agreed to acquire," not "acquired."
  • Coty divestitures. On the other side of the ledger, Coty divested its 20% stake in SKKN by Kim to Skims around March 2025 — terms undisclosed — and booked a $71.1 million loss on the divestiture; Coty has also reportedly explored a break-up sale of its Luxury and Consumer divisions (Coty announcement; WWD).

A few smaller 2025 beauty transactions round out the range and show that the mid-market trades at more sober multiples than the headline deals: LG H&H bought The Crème Shop for $190.3 million (May 30, 2025); Cosmecca bought Englewood Lab for $131.6 million at ~1.0x revenue and 8.0x EBITDA (February 6, 2025); and Helen of Troy bought Olive & June for ~$240 million on roughly $92 million of 2024 net sales, an implied ~2.6x revenue (Capstone Partners Beauty M&A Report, July 2025; Olive & June figures per Helen of Troy's announcement). The spread from Englewood Lab's ~1.0x to rhode's ~4.7x to the 5x-to-8x celebrity tail is the whole point: the multiple follows the attributes, and the attributes are what the rest of this guide is about. For the underlying valuation math — how EV/revenue and EV/EBITDA are actually built — see our M&A valuation methods guide.

What do beauty acquirers actually pay for?

Acquirers pay for retail velocity, margin structure, retailer mix quality, repeat purchase, and formula ownership — the operator-grade specifics that a revenue number alone completely hides. Two brands with identical revenue can be worth wildly different multiples, and the difference lives in the metrics below. This is the section a founder two to three years out from an exit should read most closely, because most of these are fixable if you start early.

Velocity, not just revenue. The syndicated standard for how well a brand sells is velocity — how fast product moves per point of distribution — and it is the number beauty buyers trust most. Circana (formed from the IRI and NPD merger), SPINS (the natural and specialty channel), and NielsenIQ report it as sales per $MM ACV, which normalizes for store size so a brand in a few large-format doors is comparable to one in many small ones (NielsenIQ CPG dictionary). Here is the distinction founders miss: a brand doing high velocity in limited distribution is worth more than one with wide distribution and slow sell-through, even at the same revenue, because the first has room to expand and the second is already tapped out and at risk of losing shelf on the next reset. Rising velocity is the single most persuasive line in a beauty CIM.

ACV and the quality of distribution. ACV — all-commodity volume — measures the share of total retail dollar-volume in the stores that carry you, so it reads distribution quality weighted by store size rather than a raw door count. High ACV with high velocity is the premium combination; high ACV with low velocity means you have shelf you are not earning.

Retailer mix and concentration risk. Where you sell reads differently to every buyer. Sephora and Ulta signal prestige credibility; Target signals mass reach; Amazon signals DTC-adjacent velocity and reviews; owned DTC signals margin and first-party data. But the risk that gets priced is retailer concentration — if a single retailer is a large share of your revenue, a buyer discounts for the chance that relationship changes on a reset or a category review. Diversified, growing shelf across a few strong retailers is worth a premium to a brand that is one buyer's decision away from a revenue cliff.

Margin structure. Beauty commands premium multiples in large part because prestige and masstige gross margins are high, which is why Capstone's public beauty comp set carries a ~19.9% median EBITDA margin at a 13.0x EBITDA multiple. If your margin structure is thin because you are discounting to move product or paying a co-packer a premium for small runs, that shows up as a lower multiple regardless of your top line.

Repeat rate and formula/IP ownership — the two that separate a brand from a product. A high repeat purchase rate proves you have a brand rather than a one-time viral moment. And formula ownership is the operator-grade point buyers care about most in diligence: do you own your formula, or does your contract manufacturer? An owned, documented formula — with a qualified backup manufacturer already in place — is an asset that transfers cleanly on a sale. A brand whose formula, and whose only production capacity, live entirely inside one co-packer's four walls carries real transfer risk, because a change of control can trigger renegotiation or capacity loss, and rebuilding a manufacturing relationship takes many months. That risk gets priced in every time.

Founder-brand transferability. Finally, if the brand's pull is a founder or a single creator, buyers ask whether that pull transfers. Sometimes the face stays — Hailey Bieber remained rhode's chief creative officer after the e.l.f. deal — and sometimes the diligence question is whether the brand survives the founder's attention moving on. A brand that has already broadened beyond one personality is worth more than one that has not.

Who buys beauty brands in 2026?

Three buyer classes compete for beauty brands — strategics, private equity, and holding groups — and each pays for a different thing and changes something different after close. Knowing which one is across the table tells you how to position, what they will pay up for, and what your brand will look like in two years.

Strategics — the highest multiples for the right fit. The strategic acquirers are the global beauty houses: L'Oréal, Unilever (Prestige), e.l.f. Beauty, P&G, Estée Lauder, Church & Dwight, LG H&H, and Shiseido (Capstone Partners Beauty M&A Report, July 2025). A strategic buys a brand that fills a portfolio gap — a category, a demographic, a channel it wants — and it pays the richest multiples when the asset is scarce and on-trend, because it can plug the brand into its own supply chain, shelf relationships, and international distribution. The 2025 tape is almost entirely strategics at the top: e.l.f. buying rhode (closed August 5, 2025), Church & Dwight buying Touchland (closed July 16, 2025), and Unilever buying Dr. Squatch (closed November 16, 2025). What changes post-close: the strategic integrates you into its operations and pushes your distribution harder than you could alone — and your independence goes away.

Private equity — platforms it can scale and resell. Consumer-focused PE firms buy beauty brands as platforms. L Catterton (one of the largest consumer PE firms), TSG Consumer, and Bansk Group are the active beauty names; Bansk, founded in 2019, owns Amika and Eva NYC and acquired the skincare brand BYOMA in September 2025 (Bansk / BYOMA press release). (Note that Bansk owns Amika and Eva NYC — it does not own NYX, which is L'Oréal's.) PE underwrites to a second sale, not to owning forever: it installs a growth plan, often asks the founder to roll equity for a "second bite" at the next exit, and runs a three-to-seven-year clock. What changes post-close: professionalized operations, a board, growth targets, and a countdown to the next transaction. For how these platforms aggregate and resell brands, our roll-up data room guide covers the acquirer-side mechanics — worth reading if you are being offered rollover equity, because your payout then rides on their next exit.

Holding groups and aggregators — shared operations across a portfolio. The third class rolls multiple brands onto a common back office. THG plc is the listed example: it demerged its Ingenuity technology and logistics arm in January 2025 and now positions itself as a beauty, health and wellness consumer-brands group (THG FY2025 results, Investegate). An aggregator buys for portfolio economics — shared manufacturing, distribution, and marketing infrastructure across many brands. What changes post-close: your operations get centralized into the group's shared services, which can be a strength or a loss of control depending on how your brand ran.

One consistency note on multiples across these buyers: private equity, as a class, has recently paid a premium to strategics in consumer overall, and the sub-sector spread is real — the beauty premium sits meaningfully above the broader consumer average whoever is buying. For a full map of the consumer capital partners funding these deals on the sponsor side, see our consumer independent-sponsor capital partners guide.

When is the right time to sell a beauty brand?

The right time to sell is when the brand is profitable and growing, the category has momentum, and you can run a competitive process — and the honest truth is that for a founder with real runway, the right answer is often "not yet." Timing is a value driver in its own right, because the same brand sold into strength versus weakness is a materially different number.

The market backdrop matters. Beauty M&A stayed active into 2025 — Capstone counted 28 beauty transactions announced or closed YTD 2025, pacing the prior year (Capstone Partners Beauty M&A Report, July 2025) — and strategics paid up for scarce, on-trend assets, which is exactly the environment in which a growing, profitable brand has leverage. Category momentum is real leverage: when a strategic believes a sub-category is where consumers are heading, it pays for a foothold, and being the scarce asset in a hot category is worth more than being an average asset in a flat one.

Now the harder half — the growth-versus-profitability bar, and when not to sell at all. Sell into strength, because diligence punishes weakness: a brand burning cash and hoping a sale rescues the model is exactly the brand whose normalized economics fall apart when a buyer's accountant reworks the numbers. And there are specific situations where the right move is to wait or not sell:

  • You have runway and momentum. A founder years from needing liquidity, with a brand that is compounding, can often build far more value by continuing than by selling early. Selling trades a compounding asset you own for a check and, frequently, a multi-year commitment to someone else's platform.
  • The whole story is one influencer or one retailer. If the brand's growth rests on a single creator relationship or a single retailer's shelf decision, a sophisticated buyer will discount for that fragility — and you may get a better outcome by first proving the brand persists beyond that one dependency.
  • You are reacting to a single inbound. One unsolicited approach with no competing bid gives the acquirer all the leverage. The value of a process is the tension between bidders; a sale driven by one inbound, with no alternative, structurally underprices you.
  • The window is soft. In a weak offer market the disciplined move can be to wait for the category or the buyer to come back rather than accept a discounted number.

The alternatives to selling now are not only "sell or don't" — a minority growth investment, a recapitalization, or simply more time are all on the menu. Our business exit planning guide walks through the generalist version of that decision; this section is the beauty-specific overlay on it.

How does a beauty brand sale actually run?

A beauty sale runs a defined sequence — prep, positioning, a curated buyer list, an NDA-gated staged reveal, management meetings, an LOI, confirmatory diligence, and close — and whether you run it with a banker depends heavily on your size. The mechanics are standard M&A, but the beauty-specific twist is how confidential the outreach has to be and how much diligence weight lands on scan data and manufacturing.

The stages, in order:

  1. Preparation. Get the financials clean and the story straight before anyone sees a number. This is where you build a defensible view of adjusted EBITDA — normalizing founder compensation, documenting genuine one-time costs — because a padded number gets retraded in diligence. Our quality of earnings guide covers how buyers test that number and how to prepare a package that survives them.
  2. Positioning. Frame the brand against a short, targeted list of buyers who actually fit — the strategics for whom you fill a gap, the sponsors whose thesis you match — rather than blasting the market. In beauty, a narrow, well-chosen list is both more effective and far safer for confidentiality.
  3. Outreach to a curated buyer list. Approach that list under strict confidentiality. This is the step that leaks if you are careless, and the section below is entirely about controlling it.
  4. NDA and staged reveal. Gate everything behind a non-disclosure agreement and reveal in stages — teaser first, then more as a buyer proves genuine and signs. No serious beauty process shows co-packer agreements or granular scan data before an NDA.
  5. Management meetings. The serious bidders meet the team. This is where a buyer tests whether the brand transfers beyond the founder.
  6. Letter of intent. Negotiate to an LOI with the strongest bidder(s). The LOI usually carries an exclusivity period, so the moment you sign one you have chosen a buyer and set down your leverage — do not sign it until competing interest has done its work on price.
  7. Confirmatory diligence. The buyer verifies everything (the next section details what). Deals get retraded here, or they close.
  8. Close. Signing, funding, and the start of your transition period.

The whole sequence typically runs several months from preparing for market to signing, with confirmatory diligence adding time on top. On the banker question, be honest about size. Every headline deal in this guide — rhode, Touchland, Dr. Squatch, Medik8 — was run by advisors on both sides, and above roughly $5-10 million of revenue a sell-side banker who runs a genuinely competitive process usually earns their fee by creating tension between bidders and by carrying a diligence load (scan-data reconciliation, co-packer review, chargeback history) that is heavier than most founders anticipate. Below about $5 million of revenue the calculus differs: a full auction can cost more than it returns, and a sub-$5M brand may be better served by a boutique advisor or a direct, disciplined approach to one or two logical strategics. The right answer is size-dependent, and pretending a tiny brand needs the same machinery as a $200-million-revenue deal does the founder no favors.

What will diligence dig into on a beauty brand?

Beauty diligence targets exactly the places an influencer-built P&L tends to overstate — scan data versus internal numbers, retailer deductions, co-packer agreements, inventory and expiry, MoCRA compliance, influencer contract assignability, and the trademark portfolio. This is where a padded story gets repriced, so a founder who prepares these in advance protects their number.

Here is what a serious buyer runs:

  • Scan data versus internal numbers. Buyers pull your syndicated retail data (Circana, SPINS, or NielsenIQ) and treat it as the truth, then reconcile it against what your internal reports claim. A gap between the two — internal numbers that flatter what the scan data shows — is one of the fastest ways a beauty deal gets retraded. If your reported sell-through does not match the panel, the panel wins.
  • Retailer chargebacks and deduction history. Retailer deductions and chargebacks reduce real net sales, and buyers pull the full history because a brand that reports gross while absorbing heavy deductions is worth less than it looks. This is a routine adjustment line in CPG diligence, and beauty is no exception.
  • Co-packer agreements and capacity. Every contract-manufacturer agreement gets read for capacity commitments, exclusivity, quality-audit history, and — critically — change-of-control language. A formula and production capacity that do not transfer cleanly on a sale are a priced risk, because rebuilding a manufacturing relationship can take many months and post-close capacity loss is a real threat. A qualified backup manufacturer already in place is a genuine value-protector here.
  • Inventory and expiry. Beauty products date. Buyers check inventory levels and shelf-life exposure, because aged or short-dated inventory is a write-down waiting to happen.
  • Regulatory — MoCRA. Cosmetics compliance now runs through MoCRA, the Modernization of Cosmetics Regulation Act, the federal cosmetics regime that introduced facility registration, product listing, safety-substantiation, and adverse-event-reporting requirements. Buyers confirm you are compliant, because a regulatory gap is both a cost and a liability they inherit.
  • Influencer and creator contract assignability. The creator relationships that drive a beauty brand's marketing have to be assignable to the buyer and not personally locked to a founder. A key partnership that evaporates on change of control is a diligence flag.
  • Trademark portfolio. Buyers audit your trademark registrations across every market you sell in, including any DTC-served geography, and flag gaps or opposition proceedings. Missing registrations in a market you already sell into trigger infringement and launch-delay risk.

The recurring beauty-specific kill points — the ones that most often move price or break a deal — are scan-data-versus-internal gaps, retailer concentration, and a formula that lives inside a single contract manufacturer with no backup. Prepare defensible answers to those three before you go to market. For the buyer's-eye view of how a sell-side process anticipates all of this, our sell-side due diligence guide covers running diligence on yourself before the buyer does.

How do you keep a beauty brand sale quiet in a small industry?

Beauty is a small, talkative industry, and a leaked process damages the very asset you are selling — so the entire outreach runs through a confidential, NDA-gated, per-viewer-tracked data room, revealed in stages. This is the operational core of a beauty sale, and it is where a founder most often gets hurt by being casual with documents.

Consider the leak surfaces. Your retailers talk to your competitors and to other brands. Your contract manufacturers make product for rival brands and hear everything. Your employees have friends across the category. And rival brand CEOs hear about processes fast, because everyone in beauty knows everyone. The moment the category believes you are for sale, several bad things happen at once: a retailer may hesitate on your next reset, a competitor may lean into your shelf, and your negotiating leverage drops because buyers sense a forced hand. Confidentiality is not paranoia in beauty; it is price protection.

The mechanics that keep it quiet:

  • An NDA gate on everything. Nobody sees anything beyond a blind teaser until they sign. In a staged process, the co-packer agreements and granular scan data come out only after a buyer has proven serious and signed.
  • A separate, revocable link per acquirer. Each buyer gets their own tracked link, so you can see each one's activity independently and shut any single acquirer out — the instant a process feels like it is leaking or a bidder is fishing — without disturbing the others.
  • Per-viewer watermarks. Every page carries the viewer's own identity, so a document that walks out of the room points straight back at who leaked it, which deters the leak in the first place.
  • Staged reveal. Reveal in layers as trust builds, not all at once.

This is the natural home for Peony. I run it, and it exists for exactly this confidential, multi-bidder quiet-sale job. Per-viewer dynamic watermarking and Advanced NDA with countersigning are on the $52-per-admin-per-month Data Room plan; the $30 Business plan covers a lighter process; and the free tier (up to 50 documents) lets you try the workflow before you commit. Analytics and link expiry are on every tier including Free, one-click revoke is on Business and up, viewers are always free, and storage, documents, and rooms are unlimited — so putting five acquirers into five separately-tracked rooms costs no more than putting in one. That per-viewer engagement data is also negotiating leverage: knowing which acquirer actually read your co-packer agreements and scan data, versus which one skimmed the teaser, tells you where the real interest is before you narrow the field.

What deal structures should you expect?

Expect the price to arrive in three pieces — cash at close, a performance earnout, and rollover equity — plus a multi-year founder commitment and an escrow holdback; the headline number is rarely the guaranteed number. Beauty deals lean on earnouts precisely because so much of a brand's value is a bet on continued growth, and the 2025 tape shows the pattern clearly. This is an introduction, not legal advice — run the specifics past deal counsel.

Earnouts, when growth is the story. When a buyer is paying for growth it cannot yet see, it ties part of the price to hitting revenue or EBITDA targets after close. The recent deals make this concrete: e.l.f. structured up to $200 million of the rhode purchase as a three-year earnout on top of the $800 million paid at closing, and Church & Dwight's Touchland deal carried an earn-out of up to $180 million on 2025 net sales inside its ~$880 million all-in figure. An earnout can be real upside, but only the cash at close is guaranteed — model the earnout separately, discounted for the odds you actually hit the targets, because an earnout you are 50/50 to earn is not worth its face value.

Rollover equity, with private-equity buyers. A PE buyer will often ask you to roll some of your proceeds into the platform's equity, giving you a "second bite" when they resell in a few years. That upside is real for founders who roll into a platform that keeps compounding — but the equity is illiquid, locked for the hold period, and tied to the buyer's overall performance and leverage, not your brand's. Size it as a venture-style bet, not as cash, and ask which entity's shares you are getting, whether there is a distribution history, and when the next recapitalization is expected.

Employment and transition terms. Nearly every beauty deal comes with the founder or brand face staying on for a transition — Hailey Bieber remained rhode's chief creative officer after the e.l.f. close — typically for a multi-year commitment, because the buyer paid in part for the brand's identity and wants continuity. Treat the post-sale role, its length, and its terms as part of the deal you are evaluating, not an afterthought.

Escrow and holdbacks. Expect a portion of the price to sit in escrow as a holdback against the reps and warranties you make about the business — a normal mechanism that pays out over time if no issues surface.

The single most important habit: split any offer into cash at close, contingent earnout, and illiquid rollover before you compare two of them. A higher headline built mostly on earnout and rollover can net you less, guaranteed, than a lower all-cash offer. Compare the guaranteed cash first, then risk-adjust the contingent and illiquid pieces — and have deal counsel paper every one of these structures.

Frequently asked questions

What is a beauty brand worth in 2026?

It depends far more on whether you are profitable and growing than on your revenue line. Capstone Partners' beauty M&A data puts the sector at roughly 3.6x EV/revenue (Capstone, July 2025), and Capstone's later December 2025 update pegs the beauty and personal care EV/EBITDA average at 14.9x through YTD 2025 — well above the broader consumer average of about 1.9x revenue and 11.2x EBITDA. Those are averages, and averages hide everything that matters. A profitable, fast-growing brand with clean retail velocity and an owned formula clears the bar and can command the 5x-to-8x-plus revenue that scarce, breakout, celebrity-attached brands fetch; an unprofitable DTC brand burning cash on paid acquisition often cannot get a strategic to the table at all. The recent tape frames the top end: e.l.f. Beauty bought rhode for about $1 billion in total consideration on roughly $212 million of net sales, an implied ~4.7x EV/revenue, and Church & Dwight bought Touchland at a reported ~6.8x revenue and 16.0x EBITDA. Your number is set by your margin structure, your growth rate, your retailer mix, and whether you own your formula — not by a multiple you read online.

Who buys beauty brands in 2026?

Three buyer classes, and they pay for different things. Strategics — L'Oréal, Unilever, e.l.f. Beauty, P&G, Estée Lauder, Church & Dwight, LG H&H, Shiseido — buy brands that fill a portfolio gap or a distribution channel they want, and they pay the highest multiples for scarce, on-trend assets (e.l.f./rhode, Church & Dwight/Touchland, Unilever/Dr. Squatch all closed or were agreed in 2025). Private equity — L Catterton, TSG Consumer, Bansk Group (Amika, Eva NYC, and BYOMA, which it acquired in September 2025) — buys platforms it can scale and resell, and it underwrites to a second sale, not forever. Holding groups and aggregators — THG plc's beauty division is the listed example after it demerged its Ingenuity arm in January 2025 — roll multiple brands onto shared operations. Each buyer changes something different post-close: a strategic plugs you into its supply chain and shelf, PE installs a growth plan and a clock, an aggregator centralizes your back office.

What do beauty acquirers actually pay for?

Retail velocity, margin structure, retailer mix quality, and formula ownership — in roughly that order. Velocity is the syndicated standard: how fast product sells per point of distribution, reported by Circana, SPINS, or NielsenIQ as sales per $MM ACV so it normalizes for store size. A brand doing high velocity in limited doors is worth more than one with wide distribution and slow sell-through, because the first can expand and the second is already tapped out. Buyers then look at gross margin (prestige and masstige beauty run high, which is why the category commands premium multiples), the quality of your retailer mix (Sephora, Ulta, Target, Amazon, and DTC each read differently), repeat rate, and whether you own your formula or your contract manufacturer does. An owned, documented formula with a qualified backup manufacturer is an asset that transfers cleanly; a brand whose formula and capacity live entirely inside one co-packer's four walls carries transfer risk that gets priced in.

When is the right time to sell a beauty brand?

When the brand is profitable and growing, when the category has momentum, and when you can run a real process rather than react to one inbound offer. Beauty M&A stayed active into 2025 — Capstone counted 28 beauty transactions announced or closed YTD 2025 — and strategics paid up for scarce assets, so a growing, profitable brand had leverage. The wrong time is when you are burning cash and hoping a sale rescues the model, because diligence surfaces exactly that; when the whole story is a single influencer or a single retailer you cannot prove will persist; or when you are reacting to one unsolicited approach with no competing bid to set the price. It is often not the right time at all: a founder with years of runway and real momentum may build far more value continuing to compound than by selling early into a soft window. Selling should be a decision you drive, not one a single acquirer's inbound drives for you.

How does a beauty brand sale actually run, and do I need a banker?

The process runs prep, positioning, a curated buyer list, NDA-gated staged reveal, management meetings, an LOI, confirmatory diligence, and close — typically several months from preparing for market to signing, plus diligence on top. You prepare the financials and the story, position the brand against a short, targeted list of strategics and sponsors who actually fit, gate your data behind an NDA and reveal in stages, take management meetings with the serious bidders, negotiate to a letter of intent, then survive confirmatory diligence before close. Whether you need a banker depends on size. Above roughly $5-10 million of revenue, a sell-side advisor who runs a competitive process usually pays for itself by creating tension between bidders and by handling a scan-data-and-co-packer diligence load that is heavier than most founders expect. For a sub-$5M brand the honest answer differs: the headline deals in this guide were run by bankers on both sides, but a small brand may be better served by a boutique advisor or a direct approach to one or two strategics — a full auction can cost more than it returns at that size.

What will diligence dig into on a beauty brand?

The things an influencer-built P&L tends to hide. Buyers verify your retail scan data (Circana, SPINS, or NielsenIQ) against your internal numbers and treat the syndicated read as the truth; they pull your retailer chargeback and deduction history because those reduce real net sales; they read every co-packer agreement for capacity commitments, exclusivity, and change-of-control language, because a formula and capacity that do not transfer are a priced risk; they check inventory and expiry (beauty products date); they confirm regulatory compliance, including MoCRA — the Modernization of Cosmetics Regulation Act, the federal cosmetics regime that added facility registration, product listing, safety substantiation, and adverse-event requirements; they confirm your influencer and creator contracts are assignable and not personally tied to a founder; and they audit your trademark portfolio across every market you sell in. The recurring beauty-specific kill points are scan-data-versus-internal gaps, retailer concentration, and a formula that lives inside a single contract manufacturer with no backup.

How do you let five acquirers read your co-packer agreements and scan data without the industry finding out you're for sale?

You run the whole process through one confidential data room with a separate, revocable link for each acquirer, gate everything behind an NDA, and watermark every page with the viewer's own identity so nothing screenshots cleanly onto a competitor's desk. Beauty leaks catastrophically — retailers, contract manufacturers, and rival brand CEOs all talk, and the moment a category hears you are selling, your leverage and your shelf position both wobble. I run Peony, a data room company serving 6,800+ customers, and this is the exact job it is built for: per-viewer dynamic watermarking and Advanced NDA with countersigning are on the $52-per-admin-per-month Data Room plan, the $30 Business plan covers a lighter process, and the free tier lets you pressure-test the workflow before you commit. Analytics and link expiry are on every tier, one-click revoke is on Business and up, viewers are always free, and storage, documents, and rooms are unlimited — so putting five bidders in five separately-tracked rooms costs no more than putting in one, and you can shut any single acquirer out the instant a process goes sideways without touching the others.

What deal structures should a beauty seller expect?

Earnouts, rollover equity, and multi-year founder commitments, in combinations that depend on who is buying and what the story is. When growth is the thesis, expect an earnout that ties part of the price to hitting revenue or EBITDA targets after close — e.l.f. structured up to $200 million of the rhode deal as a three-year earnout on top of the $800 million paid at closing, and Church & Dwight's Touchland deal carried a sales-based earnout inside its ~$880 million all-in figure. With a PE buyer, expect to roll some equity into the platform for a "second bite" when they resell, which is upside but illiquid and tied to their performance, not yours. Nearly every deal comes with an employment or transition agreement — a celebrity or founder face usually stays on (Hailey Bieber remained rhode's chief creative officer) — plus an escrow holdback against reps and warranties. The headline number is rarely the guaranteed number; split it into cash at close, contingent earnout, and illiquid rollover before you compare two offers, and run the specifics past deal counsel.

About the author: Chris Chen is on the M&A advisory team at Peony, the data room used by 6,800+ customers across M&A, private equity, and diligence workflows. Before Peony he worked in M&A at Moelis & Company across cross-border, healthcare, industrials, and consumer transactions, where retail velocity, formula and contract-manufacturer transferability, and retailer concentration are the facts that set the price on a beauty brand.

Sources

Related resources

You might also like

Aug 25, 2026

How to Sell a Food and Beverage Brand (2026)

ConsumerM&A

Aug 25, 2026

CPG Fundraising Data Room: What Consumer Investors Expect (2026)

FundraisingConsumer

Aug 25, 2026

How to Sell a Dental Practice in 2026: Valuation, Process, and Exit Paths

HealthcareDental